医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

WNS Launches PRECIZON to Deliver Cloud-based Competitive Intelligence for Life Sciences Industry

2021年08月03日 PM09:00
このエントリーをはてなブックマークに追加


 

NEW YORK & LONDON & MUMBAI, India

WNS (Holdings) Limited (NYSE: WNS), a leading provider of global Business Process Management (BPM) solutions, today announced the formal introduction of PRECIZON, the company’s cloud-based Competitive Intelligence (CI) platform for the Pharma, Bio-pharma and Life Sciences industry. PRECIZON provides companies with real-time CI curated from commercial and public data sources, and analyzed/presented using rich visualization techniques. The solution gives companies unprecedented access to granular data, advanced domain-centric analytics, and actionable insights resulting in enhanced decision-making and improved competitive positioning.

PRECIZON is customizable, scalable and easy-to-use, powered by WNS’ deep Pharma expertise and state-of-the-art Artificial Intelligence (AI) / Machine Learning (ML) models contextualized to CI needs. The robust AI / ML layer enables intelligence across the platform by collecting user-centric content and driving engagement. PRECIZON leverages complex search algorithms to evaluate the market landscape and drug approval timelines of competitors, providing Pharma companies with intelligent recommendations and unique views of the competitive landscape.

“Access to accurate, broad-based data sources and relevant analytical insights can give pharma companies a strategic advantage as they adapt to a complex market landscape, pricing pressures and evolving customer expectations. PRECIZON allows companies to prioritize R&D spends with a 360-degree real-time view shaped by agility, intelligent search algorithms, modularity and easy enterprise-wide access,” said Keshav R. Murugesh, Group CEO, WNS.

The platform is customizable for personalized reporting, easily integrated with existing commercial data and BI tools, and accessible across devices.

About WNS
WNS (Holdings) Limited (NYSE: WNS) is a leading Business Process Management (BPM) company. WNS combines deep industry knowledge with technology, analytics and process expertise to co-create innovative, digitally led transformational solutions with over 380 clients across various industries. WNS delivers an entire spectrum of BPM solutions including industry-specific offerings, customer experience services, finance and accounting, human resources, procurement, and research and analytics to re-imagine the digital future of businesses. As of June 30, 2021, WNS had 46,918 professionals across 57 delivery centers worldwide including facilities in Australia, China, Costa Rica, India, the Philippines, Poland, Romania, South Africa, Spain, Sri Lanka, Turkey, the United Kingdom, and the United States. For more information, visit www.wns.com.

Safe Harbor Provision
This document includes information which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events. Factors that could cause actual results to differ materially from those expressed or implied are discussed in our most recent Form 20-F and other filings with the Securities and Exchange Commission. WNS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005604/en/

CONTACT

Investors:

David Mackey

EVP–Finance & Head of Investor Relations

WNS (Holdings) Limited

+1 (646) 908-2615

david.mackey@wns.com


Media:

Archana Raghuram

Global Head – Marketing & Communications and Corporate Business Development

WNS (Holdings) Limited

+91 (22) 4095 2397

archana.raghuram@wns.com ; pr@wns.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
  • Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
  • クリアがCOVID-19声明に関する政府の訴訟に対して修正答弁書を提出、クリア製品の追加防御層としての使用を支持するデータをさらに提供
  • Integral Group Australia Rebranding as Introba to Align with Global Brands
  • 针对政府就新冠病毒声明提起的诉讼,Xlear提交修正后的答复;通过更多数据继续支持Xlear作为额外防护层使用